There are about 40 foreign pharma companies with integrated operations in Japan, each headed by a president/representative director, says P Reed Maurer, long time pharma industry watcher who is president of International Alliances Limited. 13 February 2017
A new policy released by China’s State Council, which holds the highest power in the country, aims to largely reduce vaccine injuries in the nation, reports The Pharma Letter’s local correspondent Wang Fangqing. 8 February 2017
Drug prices in Russia may increase by 20%-25% this year, due to the implementation of the latest state initiative for the introduction of mandatory QR-labelling on drugs in the local market. 3 February 2017
The pharmaceutical sector in India is set to gain rather than be impacted with the new US President Donald Trump's decision to reduce drug prices, given that the country's generic medicines are already affordable. 30 January 2017
Russia’s leading biotech firm Biocad is finishing clinical trials of a new anti-cancer drug that will soon appear in the Russian market and will be able to compete with imported analogues. 25 January 2017
Rothschild Europe, a group affiliated with Rothschild family, has called on the Russian government, as well as Andrei Belousov, Russia’s Presidential Aide, to provide support and assistance to the Russian nano and pharmaceutical producer Rusnano and the US drug giant Pfizer in their development in the Russian pharmaceutical market. 25 January 2017
Shanghai Fosun Pharmaceutical and the USA’s Kite Pharma unveiled their plan for the joint venture they are about to establish at a press meeting on Monday in Shanghai, where the JV will be located. 19 January 2017
Natsimbio, together with the local drugmaker Pharmstandard and the Italian pharmaceutical producer Kedrion Biopharma, have reached an agreement of the establishment of a joint venture for the production of drugs from human blood plasma in Russia, according to the companies. 12 January 2017
Nothing could be further from the truth than an assumption held by many Westerners that nothing changes in Japan, writes long time pharma industry watcher P Reed Maurer, who is president of International Alliances Limited. 12 January 2017
US pharma giant Pfizer has launched the production of three of its drugs in Russia, at the St Petersburg facilities of Polysan, one of the country’s leading drugmakers, reports The Pharma Letter’s local correspondent. 12 January 2017
Chronic therapies, especially anti-diabetic and cardiac care are helping the Indian pharmaceutical market notch up healthy growth figures, reports The Pharma Letter’s India correspondent. 11 January 2017
Russian drugmakers will be allowed to produce one drug under different brand names, which should help to accelerate the process of import substitution in the industry, according to a recent decision of the Russian government. 3 January 2017
The Russian General Prosecutor's Office will check information about the bribes that were allegedly paid by Teva Russia to a certain Russian top official for the assistance in the promotion its products during state tenders for public procurement of drugs in Russia. 27 December 2016
The USA’s Abbott Laboratories has officially launched a new line for the production of anti-cancer drugs at the facilities of its Russian Veropharm subsidiary in the Belgorod region, reports The Pharma Letter’s local correspondent. 22 December 2016
AstraZeneca plans to sign a special investment contract with the Russian government, which should strengthen its position in the Russian market and improve the conditions of doing business in that country. 22 December 2016
Sweeping changes are afoot at India's Health Ministry to encourage innovation in the pharmaceutical sector and to ensure speedier approvals for conducting medical research, reports The Pharma Letter's India correspondent. 21 December 2016
The Russian Federal Antimonopoly Service (FAS) has designed a mechanism for the withdrawal of licenses on the production of drugs in Russia from their rightful owners, according to Igor Artemyev, head of the FAS. 13 December 2016
Global drugmakers operating their plants in Russia have criticized the latest state initiative to introduce new restrictions on the participation of foreign drug manufacturers in tenders for the public procurement of drugs for state needs, reports The Pharma Letter’s local correspondent. 6 December 2016
Russian drugmaker Binnopharm, which is owned by the local financial conglomerate AFK Systema, may become a leading player in the Russian market of over-the-counter (OTC) drugs in the coming years, reports The Pharma Letter’s local correspondent. 6 December 2016
Some 344 fixed dose combination (FDC) medications that have been off chemists' shelves in India for some time now, are to make a reappearance, with the Delhi High Court setting aside the Indian government’s decision to ban the FDC drugs. 5 December 2016
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024